The new long-acting FGF21 analog PF-05231023 is a promising potential drug for the treatment of type 2 diabetes, obesity and obesity-related diseases (Weng et al., 2015; Thompson et al., 2016). This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.